09:51 AM EST - CML HealthCare Inc. : announced an exclusive licensing agreement with Mitomics Inc., the world's premier developer of mitochondrial DNA-based tests for early disease detection, to make available the Prostate Core Mitomic Test™ (PCMT) to Canadians. CML HealthCare Inc.
shares T.CLC are trading down $0.01 at $6.40.
